Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people with metastatic, triple-negative breast cancer.
Sacituzumab govitecan contains an antibody, similar to the cells in your body that attack diseases, that targets a protein that is common in triple-negative breast cancer. The antibody helps deliver a chemotherapy molecule directly to the tumor cells. This helps limit the side effects of the chemotherapy on the healthy cells.
Sacituzumab govitecan is an antibody-drug conjugate. These medicines include an antibody to direct the treatment to cancer cells and a chemotherapy to kill the cancer cells. Antibody-drug conjugates are designed to better target and kill cancer cells and have fewer effects on the healthy cells in your body. The antibody portion of sacituzumab govitecan targets Trop-2, a protein that is highly expressed on triple-negative breast cancer cells. The chemotherapy part is SN-38, an activated form of irinotecan.
Common side effects with sacituzumab govitecan include:
• Decreased appetite
Sacituzumab govitecan comes with warnings for neutropenia, a decrease in the level of certain white blood cells, and severe diarrhea. Neutropenia is found by your doctor through a blood test and may result in changes to your treatment. You should let your doctor know if you have any signs of infection such as fever, chills, trouble breathing, coughing, or pain while urinating. Tell your doctor immediately if you get diarrhea while taking sacituzumab govitecan. Most cases of diarrhea are resolved with medicine.
Tell your doctor about any medicines you are already taking, any existing medical conditions (especially liver problems). Sacituzumab govitecan is not recommended if you are pregnant or breastfeeding, and women should try not to become pregnant while taking it.